Reuters

07 Jun 2026, 18:32 UTC · 19h ago

Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat

Read original · https://www.reuters.com/business/healthcare-pharmaceuticals/boehringer-zealands-obesity-drug-shows-promise-cutting-visceral-liver-fat-2026-06-07/

Top 1 mover · tap to explore

Story key points

1 claims · impact-rated

What matters in this story

1
Boehringer Ingelheim's experimental obesity drug reduced visceral and liver fat while minimizing the loss of lean mass in a late-stage study. — Preserving lean mass while reducing fat is a primary clinical differentiator that could give the drug a competitive edge over existing GLP-1 therapies.
+0.60

Ticker attribution

Model heads

Sentiment in this article

No ticker sentiment head found.

Relationships in this article

No ticker relationship head found.

Early access

You’re reading about it. Someone else is already positioned.

News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.

Browse live screenings

Impact vectors

3 dimensions · 9 clusters

Analytical profile by cluster

6 related stories

GuruFocus
1d ago
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i
- clinical trials
- obesity drugs
- pharma
Read

Boehringer-Zealand's obesity drug shows promise in cutting visceral,… · News Impact Screener

Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Analytical profile by cluster

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i

Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Analytical profile by cluster

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i

Top impact dimensions

Most positively impacted

Most negatively impacted

Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising.

Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39

The Wegovy pill is still dominating the GLP-1 pill market

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Analytical profile by cluster

Next reads from the same story arc

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i

Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Analytical profile by cluster

Next reads from the same story arc

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i

Top impact dimensions

Most positively impacted

Most negatively impacted

Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising.

Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39

The Wegovy pill is still dominating the GLP-1 pill market

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial